Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study

Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.

NCT Number	NCT07757789
Lead Sponsor	New Valley University
Conditions	Antiphospholipid Syndrome
Enrollment	200 participants
Start Date	2026-07-01
Primary Completion	2027-09-25 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-11